ArticleEndocrine2025

Short-Term BRAF Inhibition with Dabrafenib induced redifferentiation in a subset of patients with BRAF V600E-Mutant papillary thyroid carcinoma.

Fabián Pitoia et al.PubMed ↗Publisher ↗

No numbers read from the abstract.